Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 1/20 | 0.45 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | CTSA | P10619 | 3/20 | 0.42 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.40 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.40 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1666942 | 0.83 | GABBR2 (0.52) | GABBR2GABBR1FFAR1 | |
| SCHEMBL2858374 | 0.82 | KMT2A (0.55) | CYP26A1ACP3CTSAGABBR2GABBR1 | |
| SCHEMBL27347770 | 0.82 | KMT2A (0.55) | CYP26A1ACP3CTSAGABBR2GABBR1 | |
| SCHEMBL3510648 | 0.82 | KMT2A (0.55) | CYP26A1ACP3CTSAGABBR2GABBR1 | |
| SCHEMBL5323449 | 0.82 | CYP26A1 (0.43) | CYP26A1ACP3CTSAGABBR2GABBR1 | |
| SCHEMBL9085971 | 0.80 | FFAR1 (0.50) | CYP26A1ACP3CTSAGPR139ATM | |
| SCHEMBL5328076 | 0.79 | ACP3 (0.46) | ACP3GPR139KIF11SMN1; SMN2PARP1 | |
| SCHEMBL27797767 | 0.78 | CYP26A1 (0.50) | CYP26A1ACP3CTSAGABBR2GABBR1 | |
| SCHEMBL5320805 | 0.77 | UGT2B7 (0.49) | GAAKMT2ASMN1; SMN2 | |
| SCHEMBL9152199 | 0.77 | CTSA (0.52) | CYP26A1ACP3CTSAGABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | CYP26A1 3699/4885ACP3 1790/4885CTSA 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.